

DMB

Display Date	6/21/99
Publication Date	6/22/99
Certifier	J. M. Windsor

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**Dermatologic and Ophthalmic Drugs Advisory Committee, Ophthalmic Drugs Subcommittee; Notice of Meeting**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

---

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Dermatologic and Ophthalmic Drugs Advisory Committee, Ophthalmic Drugs Subcommittee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on July 21, 1999, 8:30 a.m. to 5 p.m.


*Location:* Hilton Hotel, Salons A and B, 620 Perry Pkwy., Gaithersburg, MD.

*Contact Person:* Tracy Riley or Angie Whitacre, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12534. Please call the Information Line for up-to-date information on this meeting. Current information may also be accessed on the Internet at the FDA Website "www.FDA.GOV".

*Agenda:* The subcommittee will discuss new drug application (NDA) 21-023 (cyclosporine ophthalmic emulsion, 0.05%, Allergan, Inc.), for treatment of moderate to severe keratoconjunctivitis sicca.

NMI


*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the subcommittee. Written submissions may be made to the contact person by July 16, 1999. Oral presentations from the public will be scheduled between approximately 8:30 a.m. and 9:30 a.m. Time allotted for each presentation may be limited. Those desiring to make formal presentations should notify the contact person before July 16, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.




Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.

2).

Dated: 6/16/99  
June 16, 1999

  
\_\_\_\_\_  
Linda A. Suydam  
Senior Associate Commissioner

**CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL**



[FR Doc. 99-???? Filed ??-??-99; 8:45 am]

**BILLING CODE 4160-01-F**